Sanofi: Precursor Cell Lymphoblastic Leukemia-Lymphoma trials
The registry lists 11 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies with Sanofi as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 1 5Phase 2 7No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)TerminatedNCT05086315Phase 1/2Results posted
- Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid LeukemiaTerminatedNCT03860844Phase 2Results posted
- A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.CompletedNCT00315705Phase 1/2Results posted
- SAR3419 in Acute Lymphoblastic LeukemiaTerminatedNCT01440179Phase 2
- A Study of Clofarabine in Japanese Paediatric Patients With Relapsed or Refractory Acute Lymphoblastic LeukaemiaCompletedNCT01196013Phase 1
- A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)CompletedNCT00991133Phase 1
- A Phase II, Open-Label Study of Clofarabine in Paediatric Patients With Refractory/Relapsed Acute Lymphoblastic LeukaemiaCompletedNCT00930098Phase 2
- Clofarabine in Adult Patients With Advanced Solid TumorsCompletedNCT00125840Phase 1
- Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell TransplantCompletedNCT00088543Not applicable
- Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)CompletedNCT00042341Phase 2
- Aminopterin in Treating Patients With Refractory LeukemiaCompletedNCT00003305Phase 2